Compare Merck & Co., Inc. (MRK) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SkyWest Inc — how do they compare? Merck & Co., Inc. trades at $133.62 (market cap $321.77B), while SkyWest Inc trades at $107.95 (market cap $4.19B). The key difference: Merck & Co., Inc. is far larger — about 76.8× SkyWest Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| MRK | SKYW | |
|---|---|---|
Market Cap | $321.77B | $4.19B |
Sector | Health | Technology |
52-Week High | $131.84 | $123.72 |
52-Week Low | $77.60 | $78.40 |
Enterprise Value | $368.53B | $5.97B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
SkyWest (SKYW) trades at $107.57, down 0.09% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows solid fundamentals with a P/E of 10.72 and ROE of 15.34%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales and a 7.7% post-earnings rally despite misses, supported by fleet expansion and buybacks.
Outlook remains positive with a consensus price target of $109.33 and 56% buy ratings, but risks include fuel cost pressures and mixed earnings performance. The stock offers value appeal with reasonable valuation metrics, yet investor caution is warranted due to insider selling and competitive industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
